Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
There were no statistical differences in overall complication rates between the traditional and expedited groups, but there were marked savings and shorter hospital stays.
The past four years have witnessed major advancements in medical science’s drive to unravel the complexities of the human immune system. We have the COVID-19 pandemic to thank for much of the progress.
